555 related articles for article (PubMed ID: 31843945)
21. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
Jhund PS; Solomon SD; Docherty KF; Heerspink HJL; Anand IS; Böhm M; Chopra V; de Boer RA; Desai AS; Ge J; Kitakaze M; Merkley B; O'Meara E; Shou M; Tereshchenko S; Verma S; Vinh PN; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Bengtsson O; Langkilde AM; Sjöstrand M; McMurray JJV
Circulation; 2021 Jan; 143(4):298-309. PubMed ID: 33040613
[TBL] [Abstract][Full Text] [Related]
23. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
[TBL] [Abstract][Full Text] [Related]
24. Dapagliflozin-Associated Diabetic Ketoacidosis.
Chakinala RC; Chang AP; Solanki S; Haq KF; Cho R
Am J Ther; 2018; 25(6):e765-e766. PubMed ID: 29672334
[No Abstract] [Full Text] [Related]
25. Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex.
Yu MK; Vart P; Jongs N; Correa-Rotter R; Rossing P; McMurray JJV; Hou FF; Douthat W; Khullar D; Langkilde AM; Wheeler DC; Heerspink HJL; Chertow GM
J Gen Intern Med; 2024 May; 39(6):921-930. PubMed ID: 38097862
[TBL] [Abstract][Full Text] [Related]
26. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Vivian EM
Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
[TBL] [Abstract][Full Text] [Related]
27. DECLARE-TIMI 58: Participants' baseline characteristics.
Raz I; Mosenzon O; Bonaca MP; Cahn A; Kato ET; Silverman MG; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson IAM; Langkilde AM; Johansson PA; Sabatine MS; Wiviott SD
Diabetes Obes Metab; 2018 May; 20(5):1102-1110. PubMed ID: 29322605
[TBL] [Abstract][Full Text] [Related]
28. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Rev Cardiovasc Med; 2018 Jun; 19(2):41-49. PubMed ID: 31032602
[TBL] [Abstract][Full Text] [Related]
29. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
Nauck MA; Del Prato S; Durán-García S; Rohwedder K; Langkilde AM; Sugg J; Parikh SJ
Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure.
Kosiborod M; Gause-Nilsson I; Xu J; Sonesson C; Johnsson E
J Diabetes Complications; 2017 Jul; 31(7):1215-1221. PubMed ID: 28284707
[TBL] [Abstract][Full Text] [Related]
31. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis.
Yang W; Ji L; Zhou Z; Cain VA; Johnsson KM; Sjöström CD
J Diabetes; 2017 Aug; 9(8):787-799. PubMed ID: 27625142
[TBL] [Abstract][Full Text] [Related]
33. Urinary tract infections in patients with diabetes treated with dapagliflozin.
Johnsson KM; Ptaszynska A; Schmitz B; Sugg J; Parikh SJ; List JF
J Diabetes Complications; 2013; 27(5):473-8. PubMed ID: 23849632
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial.
Bajaj HS; Raz I; Mosenzon O; Murphy SA; Rozenberg A; Yanuv I; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson IAM; Sabatine MS; Wiviott SD; Cahn A
Diabetes Obes Metab; 2020 Jul; 22(7):1122-1131. PubMed ID: 32090404
[TBL] [Abstract][Full Text] [Related]
35. Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.
Idzerda NMA; Stefansson BV; Pena MJ; Sjostrom DC; Wheeler DC; Heerspink HJL
Nephrol Dial Transplant; 2020 Sep; 35(9):1570-1576. PubMed ID: 31005993
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
Yang W; Han P; Min KW; Wang B; Mansfield T; T'Joen C; Iqbal N; Johnsson E; Ptaszynska A
J Diabetes; 2016 Nov; 8(6):796-808. PubMed ID: 26589253
[TBL] [Abstract][Full Text] [Related]
37. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL
Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934
[TBL] [Abstract][Full Text] [Related]
38. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
39. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
[TBL] [Abstract][Full Text] [Related]
40. Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.
McMurray JJV; Wheeler DC; Stefánsson BV; Jongs N; Postmus D; Correa-Rotter R; Chertow GM; Greene T; Held C; Hou FF; Mann JFE; Rossing P; Sjöström CD; Toto RD; Langkilde AM; Heerspink HJL;
Circulation; 2021 Feb; 143(5):438-448. PubMed ID: 33186054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]